Role of HBV subgenotype C2, B2 in carcinogenesis, treatment and prognosis of hepatocellular carcinoma / 第二军医大学学报

ABSTRACT

Objective: To investigate the role of HBV subgenotypes B2, C2 in the carcinogenesis, treatment and prognosis of hepatocellular carcinoma (HCC). Methods: HBV genotypes and subgenotypes were detected in 462 HCC patients and 234 chronic hepatitis B (CHB) patients by a multiplex PCR assay, and HCC patients infected with HBV B2 or C2 were followed up for a year after surgical resection, transarterial chemoembolization(TACE) or a combination of both. Results: The HCC patients infected with HBV C2 had a higher chance to receive surgical treatment than those with B2 (P=0.007). Age of 40 years or older (P=0.030), male gender (P= 0.000), and viral load (>10 000 copies/ml) (P=0.017) were the independent risk factors for the carcinoge-nesis of HCC by using multivariate logistic analysis; however, there was no significant difference in the carcinogenesis of HCC between CHB patients with HBV subgenotypes B2 and C2. Age of 50 years or younger (P=0.044), infection with HBV B2 (P=0.027), and non-surgical treatment (P=0.000) were the independent risk factors for the recurrence of HCC. Thick trabecular type was more prevalent in HCC patients infected with HBV B2, C2 and genotype mixture (85.7%, 71.2% and 75.0%, respectively), and the proportions of histopathological types were not significantly different between HCC patients infected with HBV B2, C2 and genotype mixture. HBV subgenotype C2 was found in all HCC patients with rare histopathological type and subgenotype B2 and mixture were no found. Conclusion: There is no significant difference in the carcinogenesis of HCC between CHB patients with HBV subgenotypes B2 and C2. The HCC patients infected with HBV B2 have a lower chance to receive surgical treatment and are more severe than those with C2. HBV B2 is also closely associated with recurrence of HCC.